Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Orsay – page 38

3 415 clinical trials in Orsay, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Orsay at a glance
3 415
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

3 415 trials in Orsay

Open in trial search

Trisomy 21

Recruiting

Study of AEF0217 compared to placebo for improving behavior and thinking skills in adults and older adolescents with Down syndrome

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:AEF0217
  • Sponsor:Aelis Farma

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-78278343
  • Sponsor:Janssen Cilag International

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AZD8205
  • Sponsor:AstraZeneca AB

A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ninerafaxstat trihydrochloride monohydrate
  • Sponsor:Imbria Pharmaceuticals Inc.

A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Acute leukaemia

Recruiting

A Study Testing Bleximenib in People with Acute Leukemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Janssen Cilag International

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:Relay Therapeutics Inc.

A Study of MK-1084 Alone and Combined with Cetuximab for People with Advanced Solid Tumors that Have a KRAS G12C Gene Change

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Merck Sharp & Dohme LLC

A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Comparing lenalidomide and methotrexate for patients with difficult-to-treat cutaneous lupus erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Orsay

What the registry says about research in the country

01 Neurological Studies

Advanced research focusing on neurological disorders including innovative imaging studies for epilepsy, multiple sclerosis, and Huntington's disease. These trials utilize cutting-edge PET-MRI technology to better understand disease progression and treatment effectiveness.

  • Drug-resistant epilepsy imaging
  • Multiple sclerosis inflammation markers
  • Huntington's disease biomarkers

Research aims to improve diagnostic accuracy and treatment planning through advanced imaging techniques.

02 Psychiatric & Mental Health

Innovative studies exploring treatments for mental health conditions, with a focus on early psychosis and severe depression. Trials evaluate novel therapeutic approaches combining medication and digital interventions.

  • Early psychosis treatment
  • Ketamine therapy for depression
  • Personalized care approaches

Research emphasizes personalized treatment strategies and innovative therapeutic combinations.

03 Critical Care Medicine

Studies addressing critical care challenges including septic shock management and specialized treatments for severe medical conditions. Focus on improving patient outcomes in intensive care settings.

  • Septic shock delirium prevention
  • Severe hyponatremia management
  • Ventilator-associated pneumonia

Trials aim to enhance treatment protocols in critical care scenarios.

04 Oncology & Imaging

Advanced research in cancer treatment and diagnostic imaging, particularly focusing on colorectal cancer and CNS lymphoma. Studies utilize innovative imaging techniques for better disease characterization.

  • Colorectal cancer therapy
  • CNS lymphoma imaging
  • PET/MR imaging applications

Research combines cutting-edge imaging with targeted therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.